ICER Finds Geron’s Excessive Pricing of Rytelo May Limit Patient Access

The Institute for Clinical and Economic Review (ICER) determined the price set by Geron for Rytelo (imetelstat) for the treatment of anemia in patients with low-to-intermediate risk myelodysplastic syndrome (MDS) “is far out of line with the modest short term benefit suggested by the clinical trials.”
Source: Drug Industry Daily